首页 › 基金 › Rosalind Advisors, Inc. › XERS
Rosalind Advisors, Inc. 对 XERS 的持仓历史
XERIS BIOPHARMA HOLDINGS INC · 医疗保健
Rosalind Advisors, Inc. 在 Q3 2026 的 13F 申报中披露持有 XERS(XERIS BIOPHARMA HOLDINGS INC)400,000 股,市值约 US$160K,约占其申报组合的 0.07%,在其申报持仓中市值排名第 35 位。 Rosalind Advisors, Inc. 最近 12 个申报季度中有 12 个季度披露了 XERS 持仓,最早可追溯至 Q4 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Rosalind Advisors, Inc. 对 XERS 的持仓演变
Rosalind Advisors, Inc. 于 Q4 2023 首次披露 XERS 持仓:3,543,685 股(约 US$8.3M)。 该持仓在 Q2 2026 达到峰值 2,908,981 股,市值约 US$23.0M。 在 12 次申报中,Rosalind Advisors, Inc. 3 次增持、6 次减持、2 次保持不变。 最近一期申报(Q3 2026)显示持股 400,000 股、市值约 US$160K,环比减持 -2,508,981 股。。 持仓曾出现大幅变动:Q1 2026 增持约 53% (随后一个季度股价上涨 37%)、Q3 2026 减持约 86% (随后一个季度股价上涨 74%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2023 | 3.54M | $8.33M | 新进 |
| Q1 2024 | 2.82M | $6.23M | 减持 |
| Q2 2024 | 3.12M | $7.02M | 增持 |
| Q3 2024 | 3.10M | $8.85M | 持有 |
| Q4 2024 | 3.10M | $10.53M | 持有 |
| Q1 2025 | 2.50M | $13.70M | 减持 |
| Q2 2025 | 2.16M | $10.07M | 减持 |
| Q3 2025 | 1.80M | $14.62M | 减持 |
| Q4 2025 | 2.11M | $16.58M | 增持 |
| Q1 2026 | 3.23M | $18.74M | 增持 |
| Q2 2026 | 2.91M | $23.04M | 减持 |
| Q3 2026 | 400.00K | $160.00K | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 XERS 与 13F 数据
XERS(XERIS BIOPHARMA HOLDINGS INC)属于医疗保健行业。我们追踪的基金中还有 47 只申报持有 XERS,申报仓位最大的包括:Polar Asset Management Partners Inc. (US$28.8M), Parkman Healthcare Partners LLC (US$15.7M), Vilga Financial Planning LLC (US$10.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 XERS 的基金
- Polar Asset Management Partners Inc. 10.50M 股 · $28.80M · Q2 2026
- Parkman Healthcare Partners LLC 1.64M 股 · $15.70M · Q3 2026
- Vilga Financial Planning LLC 1.06M 股 · $10.13M · Q3 2026
- Knott David M Jr 1.00M 股 · $9.59M · Q3 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 693.26K 股 · $6.63M · Q3 2026
更多关于 Rosalind Advisors, Inc.
常见问题
How long has Rosalind Advisors, Inc. held XERS?
Rosalind Advisors, Inc. has disclosed XERS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Rosalind Advisors, Inc.'s current position in XERS?
As of Q3 2026, Rosalind Advisors, Inc. holds 400.00K shares of XERS (XERIS BIOPHARMA HOLDINGS INC), valued at $160.00K, representing 0.07% of its reported portfolio and ranking #35.
Has Rosalind Advisors, Inc. been buying or selling XERS?
In the latest 13F filing (Q3 2026), Rosalind Advisors, Inc. reduced its position in XERS. The position peaked in Q2 2026 at 2.91M shares.
Which other funds hold XERS?
Other major institutional holders of XERS include Polar Asset Management Partners Inc., Parkman Healthcare Partners LLC, Vilga Financial Planning LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.